According to the Russian Fund for Direct Investments, a quarter of the Mexican population will benefit from the vaccine.
Delivery is scheduled for November this year.
However, this experimental vaccine against covid-19 has not yet undergone phase 3 clinical trials, in which its efficacy is tested in humans.